Use of MHC class II ligands as adjuvant for vaccination and of LAG-3 in cancer treatment
US6410509B1 · kind B1 · utility
19Cited by
0References
22Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | Jan 27, 2000 |
| Grant date | Jun 25, 2002 |
| Priority date | — |
| Expiry date | Jan 27, 2020 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns the use of a MHC class II ligand, LAG-3, for the manufacture of a medicament for preventing or treating pathological conditions involving an antigen specific immune response, as well as the use of LAG-3 in cancer immunotherapy. The invention also concerns a pharmaceutical composition comprising an effective amount of an antigen together with an effective amount of human LAG-3, wherein LAG-3 s present as an adjuvant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.